PTEN基因与肿瘤耐药  

Role of PTEN in resistance to anti-cancer drugs

作　　者：吴新刚[1] 闾四平[1] 

机构地区：[1]湖南省岳阳职业技术学院医学基础部,岳阳414000

出　　处：《中国新药杂志》2008年第15期1291-1294,共4页Chinese Journal of New Drugs

摘　　要：肿瘤对抗肿瘤药物产生耐受性是肿瘤内科治疗失败的主要原因。PTEN是一种具有双特异性磷酸酶活性的抑瘤基因,其失活与多种肿瘤的发生发展密切相关。近年来的研究表明,PTEN在肿瘤耐药中发挥着重要作用。PTEN失活可介导肿瘤对表皮生长因子受体(EGFR)酪氨酸激酶抑制剂、抗Her-2/ErbB2人源化单克隆抗体曲妥珠单抗(trastuzumab)、抗EGFR人/鼠嵌合型单克隆抗体西妥昔单抗(cetuximab)、NOTCH1抑制剂、顺铂、阿霉素和紫杉醇等的耐受性,其机制与PTEN对PI3K-AKT信号途径的抑制有关。现综述PTEN基因的生物学特性及其在近年研究较多的几种肿瘤靶向药物耐药中的作用特征。Resistance to anti-cancer drug is an important clinical problem even in the age of targeted therapeutics and tailored treatment approaches. PTEN is a tumor suppressor gene with a dual specificity phosphatase activity, whose inactivation is correlated to the development of some tumors. Recently, many studies have shown that PTEN plays an important role in resistance to anti-cancer drug. Inactivation of PTEN confers resistance of cancer to EGFR kinase inhibitors, trastuzumab（Herceptin）, cetuximab（Erbitux）, NOTCH1 inhibitors, cisplatin, doxorubicin and paclitaxel. The mechanism involves the role of PTEN in the PI3K-AKT pathway.

关 键 词：PTEN基因 化疗 肿瘤多药耐药 

分 类 号：R979.1[医药卫生—药品] R730.53[医药卫生—药学]